

# Untitled

AAE19112

ID AAE19112 standard; protein; 117 AA.

XX

AC AAE19112;

XX

DT 21-MAY-2002 (first entry)

XX

DE Human NKp46D2 (isoform b) protein.

XX

KW Human; natural killer cell activating protein; NKp46; therapy; virucide;  
KW viral infection; natural killer cell; NK; NKp44; imaging agent; cancer;  
KW detection; carcinoma; melanoma; lymphoma; sarcoma; cytostatic.

XX

OS Homo sapiens.

XX

PN W0200208287- A2.

XX

PD 31-JAN-2002.

XX

PF 19-JUL-2001; 2001W0-IL000664.

XX

PR 20-JUL-2000; 2000IL-00137419.

XX

PA (YISS) YISSUM RES DEV CO HEBREW UNI V JERUSALEM

PA (UYNE) UNI V BEN-GURION NEGEV.

XX

PI Mandelboim O, Porgador A;

XX

DR WPI; 2002-195870/25.

DR N-PSDB; AAD30469.

XX

PT New targeting complex capable of targeting an active substance to a  
PT target cell, comprising a target recognition segment and an active  
PT segment, useful for treating pathologies associated with viral infections  
PT or cancer.

XX

PS Claim 4; Page 111-112; 113pp; English.

XX

CC The invention relates to compositions and methods for the treatment and  
CC detection of a variety of viral infections, by using complex agents  
CC comprising the natural killer (NK) cells activating proteins, NKp46 and  
CC NKp44 and functional fragments thereof, linked to therapeutic or imaging  
CC agents. The complex is useful for treating pathologies associated with  
CC viral infections (e.g. infections caused by influenza virus, HIV, Epstein  
CC -Barr virus, cytomegalovirus, vaccinia virus, ECMV, MCM or herpes virus)  
CC and cancer (e.g. carcinomas, melanomas, lymphomas and sarcomas), and for  
CC the imaging and monitoring of cancer. The complex may also be used to  
CC detect the presence of abnormal cells in a sample. The antibodies can be  
CC used to qualitatively or quantitatively detect the ligand for the  
CC complex. The present sequence is human NKp46 (isoform b) domain 2

XX

SQ Sequence 117 AA;

Query Match 100.0% Score 102; DB 5; Length 117;  
Best Local Similarity 100.0% Pred. No. 6.2e-09;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FLLLLKEGRSSHVQRGYGVQ 20  
| | | | | | | | | | | | | | | | | | | | | |  
Db 33 FLLLLKEGRSSHVQRGYGVQ 52

\*\*\*\*\*  
\*\*\*\*\*

# Untitled

AAE19109

ID AAE19109 standard; protein; 135 AA.

XX

AC AAE19109;

XX

DT 21-MAY-2002 (first entry)

XX

DE Human NKp30 protein.

XX

KW Human; natural killer cell activating protein; NKp46; therapy; virucide;

KW viral infection; natural killer cell; NK; NKp44; imaging agent; cancer;

KW detection; carcinoma; melanoma; lymphoma; sarcoma; cytostatic; NKp30.

XX

OS Homo sapiens.

XX

PN W0200208287-A2.

XX

PD 31-JAN-2002.

XX

PF 19-JUL-2001; 2001W01L000664.

XX

PR 20-JUL-2000; 2000IL-00137419.

XX

PA (YISS) YISSUM RES DEV CO HEBREW UNI V JERUSALEM

PA (UYNE) UNI V BEN-GURION NEGEV.

XX

PI Mandelboim O, Porgador A;

XX

DR WPI; 2002-195870/25.

DR N-PSDB; AAD30466.

XX

PT New targeting complex capable of targeting an active substance to a  
PT target cell, comprising a target recognition segment and an active  
PT segment, useful for treating pathologies associated with viral infections  
PT or cancer.

XX

PS Example 1; Page 108; 113pp; English.

XX

CC The invention relates to compositions and methods for the treatment and  
CC detection of a variety of viral infections, by using complex agents  
CC comprising the natural killer (NK) cells activating proteins, NKp46 and  
CC NKp44 and functional fragments thereof, linked to therapeutic or imaging  
CC agents. The complex is useful for treating pathologies associated with  
CC viral infections (e.g. infections caused by influenza virus, HIV, Epstein  
CC -Barr virus, cytomegalovirus, vaccinia virus, ECMV, MCM or herpes virus)  
CC and cancer (e.g. carcinomas, melanomas, lymphomas and sarcomas), and for  
CC the imaging and monitoring of cancer. The complex may also be used to  
CC detect the presence of abnormal cells in a sample. The antibodies can be  
CC used to qualitatively or quantitatively detect the ligand for the  
CC complex. The present sequence is human NKp30 protein

XX

SQ Sequence 135 AA;

Query Match 100.0% Score 143; DB 5; Length 135;

Best Local Similarity 100.0% Pred. No. 1.5e-13;

Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RDEVWPGKEVRNGTPEFRGLAPLASSR 28

Db 57 RDEVWPGKEVRNGTPEFRGLAPLASSR 84

\*\*\*\*\*

\*\*\*\*

AAE19109

ID AAE19109 standard; protein; 135 AA.

XX

AC AAE19109;

XX

DT 21-MAY-2002 (first entry)

XX

DE Human NKp30 protein.

XX

KW Human; natural killer cell activating protein; NKp46; therapy; virucide;

KW viral infection; natural killer cell; NK; NKp44; imaging agent; cancer;

KW detection; carcinoma; melanoma; lymphoma; sarcoma; cytostatic; NKp30.

XX

OS Homo sapiens.

XX

PN W0200208287-A2.

XX

PD 31-JAN-2002.

XX

PF 19-JUL-2001; 2001W01L000664.

XX

PR 20-JUL-2000; 2000IL-00137419.

XX

PA (YISS) YISSUM RES DEV CO HEBREW UNI V JERUSALEM

PA (UYNE) UNI V BEN-GURION NEGEV.

XX

PI Mandelboim O, Porador A;

XX

DR WPI; 2002-195870/25.

DR

N-PSDB; AAD30466.

XX

PT New targeting complex capable of targeting an active substance to a  
PT target cell, comprising a target recognition segment and an active  
PT segment, useful for treating pathologies associated with viral infections  
PT or cancer.

XX

PS Example 1; Page 108; 113pp; English.

XX

CC The invention relates to compositions and methods for the treatment and  
CC detection of a variety of viral infections, by using complex agents  
CC comprising the natural killer (NK) cells activating proteins, NKp46 and  
CC NKp44 and functional fragments thereof, linked to therapeutic or imaging  
CC agents. The complex is useful for treating pathologies associated with  
CC viral infections (e.g. infections caused by influenza virus, HIV, Epstein  
CC -Barr virus, cytomegalovirus, vaccinia virus, ECMV, MCM or herpes virus)  
CC and cancer (e.g. carcinomas, melanomas, lymphomas and sarcomas), and for  
CC the imaging and monitoring of cancer. The complex may also be used to  
CC detect the presence of abnormal cells in a sample. The antibodies can be  
CC used to qualitatively or quantitatively detect the ligand for the  
CC complex. The present sequence is human NKp30 protein

XX

SQ Sequence 135 AA;

Query Match 100.0% Score 107; DB 5; Length 135;

Best Local Similarity 100.0% Pred. No. 1.4e-08;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 RDEVVPGKEVRNGTPEFRGR 20

Db 57 RDEVVPGKEVRNGTPEFRGR 76

# Untitled

AAE19105

ID AAE19105 standard; protein; 190 AA.

XX

AC AAE19105;

XX

DT 21-MAY-2002 (first entry)

XX

DE Human NKp44 protein.

XX

KW Human; natural killer cell activating protein; NKp46; therapy; virucide;

KW viral infection; natural killer cell; NK; NKp44; imaging agent; cancer;

KW detection; carcinoma; melanoma; lymphoma; sarcoma; cytostatic.

XX

OS Homo sapiens.

XX

PN ~~WO~~200208287- A2.

XX

PD 31- JAN- 2002.

XX

PF 19- JUL- 2001; 2001~~WO~~- IL000664.

XX

PR 20- JUL- 2000; 2000IL- 00137419.

XX

PA ( YI SS ) YI SSUM RES DEV CO HEBREW UNI V JERUSALEM

PA ( UYNE ) UNI V BEN- GURI ON NEGEV.

XX

PI Mandel boi m Q, Por gador A;

XX

DR ~~WPI~~; 2002- 195870/ 25.

DR N- PSDB; AAD19105.

XX

PT New targeting complex capable of targeting an active substance to a

PT target cell, comprising a target recognition segment and an active

PT segment, useful for treating pathologies associated with viral infections

PT or cancer.

XX

PS Claim 6; Page 101; 113pp; English.

XX

CC The invention relates to compositions and methods for the treatment and

CC detection of a variety of viral infections, by using complex agents

CC comprising the natural killer (NK) cells activating proteins, NKp46 and

CC NKp44 and functional fragments thereof, linked to therapeutic or imaging

CC agents. The complex is useful for treating pathologies associated with

CC viral infections (e.g. infections caused by influenza virus, HIV, Epstein

CC -Barr virus, cytomegalovirus, vaccinia virus, ECMV, MCM or herpes virus)

CC and cancer (e.g. carcinomas, melanomas, lymphomas and sarcomas), and for

CC the imaging and monitoring of cancer. The complex may also be used to

CC detect the presence of abnormal cells in a sample. The antibodies can be

CC used to qualitatively or quantitatively detect the ligand for the

CC complex. The present sequence is human NKp44 protein

XX

SQ Sequence 190 AA;

Query Match 100.0% Score 127; DB 5; Length 190;

Best Local Similarity 100.0% Pred. No. 6.5e-12;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KKG~~W~~KEASALVCI RLVTSSKPRT 24

Db 51 KKG~~W~~KEASALVCI RLVTSSKPRT 74

Untitled

\*\*\*\*\*  
\*\*